Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | ACACA | Q13085 | 3/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | RXRB | P28702 | 2/20 | 0.45 |
| ▸ | RXRG | P48443 | 2/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349045 | 0.91 | PPARD (0.49) | FFAR4FFAR1PPARDPPARGACACB | |
| SCHEMBL6348828 | 0.85 | GRM2 (0.54) | FFAR4FFAR1MCL1BAK1RXRA | |
| SCHEMBL6416751 | 0.84 | MAOB (0.52) | FFAR4FFAR1PPARDPPARGACACB | |
| SCHEMBL6346488 | 0.84 | CTSV (0.46) | FFAR4FFAR1ACACBACACAMCL1 | |
| SCHEMBL6341556 | 0.84 | ALOX5 (0.51) | FFAR4FFAR1PPARGACACBACACA | |
| SCHEMBL6338656 | 0.83 | ACACB (0.55) | FFAR4FFAR1ACACBACACA | |
| SCHEMBL6338589 | 0.83 | ALDH1A1 (0.44) | FFAR4FFAR1 | |
| SCHEMBL6341725 | 0.83 | OPRM1 (0.47) | FFAR4FFAR1ACACBACACARXRA | |
| SCHEMBL2793815 | 0.80 | FFAR4 (0.74) | FFAR4FFAR1RXRARXRBRXRG | |
| SCHEMBL6337468 | 0.80 | MEN1 (0.46) | FFAR4FFAR1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890932-B2 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1101755-B1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | TEIJIN LIMITED | 2003-12-18 | — | — | US | disclosed |
| US-6649656-B1 | Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents | TEIJIN LIMITED (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1101755-A1 | ANTHRANILIC ACID DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232811-A1 | Immunoglobulin e antibody suppressors | IGLV6-57, FCGRT, IGSF11 | FFAR4 2194/4885FFAR1 1564/4885PPARD 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.